Enveric Biosciences マネジメント

マネジメント基準チェック /34

Enveric Biosciencesの CEO はJoseph Tuckerで、 Sep2021年に任命され、の在任期間は 3.17年です。の年間総報酬は$ 577.07Kで、 78.1%給与と21.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.33%を直接所有しており、その価値は€ 8.99K 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と2.3年です。

主要情報

Joseph Tucker

最高経営責任者

US$577.1k

報酬総額

CEO給与比率	78.1%
CEO在任期間	3.2yrs
CEOの所有権	0.3%
経営陣の平均在職期間	3.2yrs
取締役会の平均在任期間	2.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Enveric Biosciences の収益と比較して、Joseph Tucker の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$577k	US$451k	-US$17m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$826k	US$362k	-US$19m
Sep 30 2022	n/a	n/a	-US$52m
Jun 30 2022	n/a	n/a	-US$52m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	US$3m	US$92k	-US$49m

報酬と市場: Josephの総報酬 ($USD 577.07K ) は、 German市場 ($USD 474.54K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Josephの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Joseph Tucker (55 yo)

3.2yrs

在職期間

US$577,065

報酬

Dr. Joseph Tucker, Ph D., has been a Director of Enveric Biosciences, Inc. since September 16, 2021. Dr. Tucker has been the Chief Executive Officer of Enveric Biosciences, Inc. since September 16, 2021.D...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Joseph Tucker	CEO & Director	3.2yrs	US$577.07k	0.33% € 9.0k
Kevin Coveney	Chief Financial Officer	1.7yrs	US$435.31k	0.074% € 2.0k
Peter Facchini	Chief Innovation Officer	3.2yrs	US$282.06k	0.22% € 6.1k

3.2yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: SLZAの経営陣は経験豊富であると考えられます ( 3.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Joseph Tucker	CEO & Director	3.2yrs	US$577.07k	0.33% € 9.0k
Michael Webb	Independent Chairman of the Board	2.4yrs	US$175.00k	0.54% € 14.7k
Sheila DeWitt	Independent Director	less than a year	データなし	0.31% € 8.6k
Stephen Stahl	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Frank Pasqualone	Independent Director	2.3yrs	US$57.50k	0.55% € 15.0k
Maurizio Fava	Chairman of Scientific Advisory Board	2.3yrs	データなし	データなし
Michael Liebowitz	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
John Krystal	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Marcus Schabacker	Independent Non-Employee Director	3.9yrs	US$52.00k	0.54% € 14.8k
George Kegler	Independent Non-Employee Director	3.9yrs	US$59.00k	0.54% € 14.8k

2.3yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: SLZAの取締役会は経験豊富ではない ( 2.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Enveric Biosciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

New major risk - Financial position

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

New major risk - Share price stability

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

New major risk - Share price stability

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

High number of new and inexperienced directors

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34